Vaccination: Manufacturing Industries

Department of Health and Social Care written question – answered at on 8 September 2023.

Alert me about debates like this

Photo of John Spellar John Spellar Labour, Warley

To ask the Secretary of State for Health and Social Care, with reference to his Department’s paper A review of the Vaccine Taskforce, published on 29 August 2023, what funds the Office for Life Sciences has to invest in additional vaccine production capacity in the UK in order to achieve the onshoring programme objective set for the Vaccines Taskforce.

Photo of Maria Caulfield Maria Caulfield The Parliamentary Under-Secretary for Health and Social Care, Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)

Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom’s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.